The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy

Clinical Cancer Research

Volumn 3, Issue 5, 1997, Pages 805-815

  Noordzij, Marinus A ^a   Van Steenbrugge, Gert Jan ^a   Verkaik, Nicole S ^a   Schröder, Fritz H ^a   Van Der Kwast, Theodorus H ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; EXON; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSURETHRAL RESECTION;

ANTIGENS, CD44; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EXONS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL ANALYSIS; TIME FACTORS; TRANSCRIPTION, GENETIC;

EID: 0030997602     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. van der Gulden, J. W. J., Kiemeney, L. A. L. M., Verbeek, A. L. M., and Straatman, H. Mortality trends from prostate cancer in The Netherlands (1950-1989). Prostate, 24: 33-38, 1994.
2. Zhau, H. E., Pisters, L. L., Hall, M. C., Zhao, L. S., Troncoso, P., Pollack, A., and Chung, L. W. K. Biomarkers associated with prostate cancer progression. J. Cell. Biochem., 19 (Suppl.): 208-216, 1994.
3. Jacobsen, S. J., Katusic, S. K., Bergstralh, E. J., Oesterling, J. E., Ohrt, D., Klee, G. G., Chute, C. G., and Lieber, M. M. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. J. Am. Med. Assoc. 274: 1445-1449, 1995.
4. Mettlin, C. J., Murphy, G. P., Ho, R., and Menck, H. R. The national cancer data base report on longitudinal observations on prostate cancer. Cancer (Phila.), 77: 2162-2166, 1996.
5. Bubendorf, L., Sauter, G., Moch, H., Schmid, H. P., Gasser, T. C., Jordan, P., and Mihatch, M. J. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J. Pathol., 178: 437-441, 1996.
6. Umbas, R., Isaacs, W. B., Bringuier, P. B., Schaafsma, H. E., Karthaus, H. F. M., Oosterhof, G. O. N., Debruyne, F. M. J., and Schalken, J. A. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res., 54: 3929-3933, 1994.
7. Matsumura, Y., and Tarin, D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet, 340: 1053-1058, 1992.
8. Mackay, C. R., Terpe, H-J., Stauder, R., Marston, W. L., Stark, H., and Gunthert, U. Expression and modulation of CD44 variant isoforms in humans. J. Cell Biol., 124: 71-82, 1994.
9. Fox, S. B., Fawcett, J., Jackson, D. G., Collins, I., Gatter, K. C., Harris, A. L., Gearing, A., and Simmons, D. L. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res., 54: 4539-4546, 1994.
10. Screaton, G. R., Bell, M. V., Jackson, D. G., Cornelis, F. B., Gerth, U., and Bell, J. I. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc. Natl. Acad. Sci. USA, 89: 12160-12164, 1992.
11. Gunthert, U., Hofmann, M., Ruby, W., Reber, S., Zoller, M., Haussmann, I., Matzku, S., Wenzel, A., Ponta, H., and Herrlich, D. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell, 65: 13-24, 1991.
12. Mulder, J. W. R., Kruyt, P. M., Sewnath, M., Oosting, J., Seldenrijk, C. A., Weidema, W. F., Offerhaus, G. J. A., and Pals, S. T. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet, 344: 1470-1472, 1994.
13. Kaufmann, M., Heider, K-H., Sinn, H-P., Von Minckwitz, G., Ponta, H., and Herrlich, P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet, 345: 615-619, 1995.
14. Stauder, R., Eisterer, W., Thaler, J., and Gunthert, U. CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood, 85: 2885-2899, 1995.
15. Combaret, V., Lasset, C., Frappaz, D., Bouvier, R., Thiesse, P., Rebillard, A-C., Philip, T., and Favrot, M. C. Evaluation of CD44 prognostic value in neuroblastoma: comparison with other prognostic factors. Eur. J. Cancer, 31A: 545-549, 1995.
16. Stevens, J. W., Palechek, P. L., Griebling, T. L., Midura, R. J., Rokhlin, O. W., and Cohen, M. B. Expression of CD44 isoforms in human prostate tumor cell lines. Prostate, 28: 153-161, 1996.
17. Schröder, F. H., Hermanek, P., Denis, L., Fair, W. R., Gospodarowicz, M. K., and Macaluso, P. The TNM classification of prostate cancer. Prostate, 4 (Suppl.): 129-138, 1992.
18. Bostwick, D. G., and Brawer, M. K. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer (Phila.), 59: 788-794, 1987.
19. Koopman, G., Heider, K. H., Horst, E., Adolf, G. R., van den Berg, G., Ponta, H., Herrlich, P., and Pals, S. T. Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J. Exp. Med., 177: 897-904, 1993.
20. Wielenga, V. J. M., Heider, K. H., Offerhaus, G. J. A., Adolf, G. R., van den Berg, F. M., Ponta, H., Herrlich, P., and Pals, S. T. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res., 53: 4754-4756, 1993.
21. Kainz, C., Kohlberger, P., Sliutz, G., Tempfer, C., Heinzl, H., Reinthaller, A., Breitenecker, G., and Koelbl, H. Splice variants of CD44 in human cervical cancer stage IB to IIB. Gynecol. Oncol., 57: 383-387, 1995.
22. Adams, J. C. Biotin amplification of biotin and horseradish peroxidase signals in histochemical stains. J. Histochem. Cytochem., 40: 1457-1463, 1992.
23. Hsu, S. M., Raine, L., and Fanger, H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem., 29: 577-580, 1981.
24. Maddox, P. H., and Jenkins, D. 3-Aminopropyltriethoxysilane (APES): a new advance in section adhesion. J. Clin. Pathol., 40: 1256-1257, 1987.
25. Shi, S. R., Key, M. E., and Kalra, K. L. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J. Histochem. Cytochem., 39: 741-748, 1991.
26. Friedrichs, K., Franke, F., Lisboa, B-W., Kügler, G., Gille, I., Terpe, H-J., Hölzel, F., Maass, H., and Günthert, U. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res., 55: 5424-5433, 1995.
27. Lokeshwar, B. L., Lokeshwar, V. B., and Block, N. L. Expression of CD44 in prostate cancer cells: association with cell proliferation and invasive potential. Anticancer Res., 15: 1191-1198, 1995.
28. Liu, A. Y. Expression of CD44 in prostate cancer cells. Cancer Lett., 79: 63-69, 1993.
29. Welsh, C. F., Zhu, D., and Bourguignon, L. Y. W. Interaction of CD44 variant isoforms with hyaluronic acid and the cytoskeleton in human prostate cancer cells. J. Cell. Physiol., 164: 605-612, 1995.
30. Sanger, F., Nicklen, S., and Coulson, A. R. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA, 74: 5463-5467, 1977.
31. Tarin, D., and Matsumura, Y. Deranged activity of the CD44 gene and other loci as biomarkers for progression to metastatic malignancy. J. Cell. Biochem., 17G: 173-185, 1993.
32. Corless, C. L. Evaluating early-stage prostate cancer: what treatment criteria best guide therapeutic decision making? Hematol. Oncol. Clin. North Am., 10: 565-579, 1996.
33. Washington, K., Gottfried, M. R., and Telen, M. J. Expression of the cell adhesion molecule CD44 in gastric adenocarcinoma. Hum. Pathol., 25: 1043-1049, 1994.
34. Kainz, C., Kohlberger, P., Tempfer, C., Sliutz, G., Gitsch, G., Reinthaller, A., and Breitenecker, G. Prognostic value of CD44 splice variants in human stage III cervical cancer. Eur. J. Cancer, 31A: 1706-1709, 1995.
35. Joensuu, H., Klemi, P. J., Toikkanen, S., and Jalkanen, S. Glycoprotein CD44 expression and its association with survival in breast cancer. Am. J. Pathol., 143: 867-874, 1993.
36. Cannistra, S. A., Abu-Jawdeh, G., Niloff, J., Strobel, T., Swanson, L., Andersen, J., and Ottensmeier, C. CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. J. Clin. Oncol., 13: 1912-1921, 1995.
37. Salmi, M., Gron-Virta, K., Sointu, P., Grenman, R., Kalimo, H., and Jalkanen, S. Regulated expression of exon v6 containing isoforms of CD44 in man: downregulation during malignant transformation of tumors of squamocellular origin. J. Cell Biol., 122: 431-442, 1993.